Non-muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast–2032

January 2022 | 60 pages | ID: N14DDB935980EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Non-muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Non-muscle Invasive Bladder Cancer (NMIBC) Understanding

The DelveInsight Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology report gives a thorough understanding of the Non-muscle Invasive Bladder Cancer (NMIBC) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Non-muscle Invasive Bladder Cancer (NMIBC) in the US, Europe, and Japan. The report covers the detailed information of the Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology scenario in seven major countries (US, EU5, and Japan).

Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Perspective by DelveInsight

The Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Non-muscle Invasive Bladder Cancer (NMIBC) Detailed Epidemiology Segmentation

The Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology covered in the report provides historical as well as forecasted Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Non-muscle Invasive Bladder Cancer (NMIBC) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Non-muscle Invasive Bladder Cancer (NMIBC) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Report and Model provide an overview of the global trends of Non-muscle Invasive Bladder Cancer (NMIBC) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Non-muscle Invasive Bladder Cancer (NMIBC) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Non-muscle Invasive Bladder Cancer (NMIBC)
• The report provides the segmentation of the Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology

Report Highlights

• 11-year Forecast of Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Non-muscle Invasive Bladder Cancer (NMIBC)
• Cases of Non-muscle Invasive Bladder Cancer (NMIBC) by Mutation Types
• Non-muscle Invasive Bladder Cancer (NMIBC) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Non-muscle Invasive Bladder Cancer (NMIBC) ?
• What are the key findings pertaining to the Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Non-muscle Invasive Bladder Cancer (NMIBC) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Non-muscle Invasive Bladder Cancer (NMIBC) ?
• What are the currently available treatments of Non-muscle Invasive Bladder Cancer (NMIBC) ?

Reasons to buy

The Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Non-muscle Invasive Bladder Cancer (NMIBC) market
• Quantify patient populations in the global Non-muscle Invasive Bladder Cancer (NMIBC) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Non-muscle Invasive Bladder Cancer (NMIBC) therapeutics in each of the markets covered
• Understand the magnitude of Non-muscle Invasive Bladder Cancer (NMIBC) population by its epidemiology
• The Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

3. NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) : DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Non-muscle Invasive Bladder Cancer (NMIBC) Treatment and Management
6.2. Non-muscle Invasive Bladder Cancer (NMIBC) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in 7MM (2019-2032)
Table 2: Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in the United States (2019-2032)
Table 4: Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in Germany (2019-2032)
Table 6: Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in France (2019-2032)
Table 8: Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in Italy (2019-2032)
Table 10: Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in Spain (2019-2032)
Table 12: Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in the United Kingdom (2019-2032)
Table 14: Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in Japan (2019-2032)
Table 16: Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in 7MM (2019-2032)
Figure 2 Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in the United States (2019-2032)
Figure 4 Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in Germany (2019-2032)
Figure 6 Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in France (2019-2032)
Figure 8 Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in Italy (2019-2032)
Figure 10 Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in Spain (2019-2032)
Figure 12 Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology in Japan (2019-2032)
Figure 16 Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report